FindTrial
Sign In

DW-MRI in mediastinal restaging after concomitant chemoradiotherapy and prognosis of trimodality treatment for stage IIIA/B NSCLC with mediastinal lymph node metastases and without supraclavicular lymph node metastases ; NSCLC Stadium IIIA/B N2/3

DW-MRI in mediastinal restaging after concomitant chemoradiotherapy and prognosis of trimodality treatment for stage IIIA/B NSCLC with mediastinal lymph node metastases and without supraclavicular lymph node metastases ; NSCLC Stadium IIIA/B N2/3 - MRI in trimodality treatment for locally advanced NSCLC

Status
Unknown
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON43810
Enrollment
50
Registered
2016-12-20
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lungcancer Non-small cell lung cancer

Interventions

None listed

Sponsors

Sint Antonius Ziekenhuis
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients between 18-76 years old, diagnosed with locally advanced NSCLC with pathologic proven (cytology or histology) mediastinal lymph node metastasis, without supraclaviculair lymph node metastasis, stage III A and B N2/3. Patients are planned for treatment with concomitant chemoradiotherapy.

Exclusion criteria

Exclusion criteria: Supraclaviculair lymph node metastasis or distant metastasis Other potential curative treatment options Mixed tumor types with small cell lung cancer Expected need for pneumonectomy right lung Participation in other trial with investigational drug or treatment modality Contraindications MRI

Design outcomes

Primary

MeasureTime frame
Main study parameters/endpoints: Determination of the feasibility to use DW-MRI in the evaluation of treatment response during and after chemoradiotherapy treatment for locally advanced NSCLC compared to the pathological specimen as gold standard.—

Secondary

MeasureTime frame
nvt—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)